Life sciences investment firm Malin Corporation has had a bumpy ride since its €330 million flotation on the Irish Stock Exchange was celebrated back in March 2015 as one of the largest IPOs in its sector in Europe.  Hailed by then taoiseach Enda Kenny as “a boost to Ireland’s reputation as the best small country in the world for business”, the investment portfolio of the med-tech group struggled to hit gold despite its impressive war chest and stakeholders that included the state’s sovereign wealth fund ISIF. On paper it was immaculate, set up by former Elan executives including CEO Kelly…

Want to continue reading?

Introductory offer: Sign up today and pay €200 for an annual membership, a saving of €100.

Subscribe

Cancel anytime.

Are you already a member? .